Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

NCT06568471 is registered in ClinicalTrials.gov with Hasten Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06568471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06568471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
Lead sponsor
Hasten Biopharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
November 16, 2024
Completion date
May 31, 2026
Enrollment
210 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

ascvd, dyslipidemias, heterozygous familial hypercholesterolemia, hypercholesterolemia, hyperlipidemia; mixed, metabolic disease, primary hypercholesterolemia